Endo International PLC (NASDAQ:ENDP) CEO Paul Campanelli bought 6,500 shares of Endo International PLC stock in a transaction dated Monday, August 14th. The shares were acquired at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Endo International PLC (NASDAQ ENDP) traded up 6.450% during midday trading on Wednesday, reaching $8.665. The company’s stock had a trading volume of 5,146,200 shares. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $24.93. The firm has a 50 day moving average price of $10.70 and a 200-day moving average price of $11.49. The company’s market cap is $1.93 billion.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same period last year, the business posted $0.86 EPS. The business’s revenue was down 4.9% compared to the same quarter last year. On average, equities research analysts predict that Endo International PLC will post $3.52 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/16/endo-international-plc-endp-ceo-purchases-50115-00-in-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Macquarie Group Ltd. increased its position in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares in the last quarter. Americafirst Capital Management LLC bought a new position in shares of Endo International PLC during the first quarter worth about $286,000. Hartford Investment Management Co. bought a new position in shares of Endo International PLC during the first quarter worth about $1,363,000. Nationwide Fund Advisors increased its position in shares of Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares in the last quarter. Finally, First Quadrant L P CA bought a new position in shares of Endo International PLC during the first quarter worth about $24,556,000. Institutional investors and hedge funds own 92.27% of the company’s stock.

Several research firms have recently issued reports on ENDP. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Endo International PLC in a research note on Tuesday, August 8th. Royal Bank Of Canada set a $9.00 target price on Endo International PLC and gave the company a “hold” rating in a research note on Thursday, August 10th. Cowen and Company reissued a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a research note on Thursday, August 10th. Guggenheim began coverage on Endo International PLC in a research note on Saturday, June 17th. They set a “hold” rating and a $12.00 target price on the stock. Finally, Deutsche Bank AG set a $13.00 target price on Endo International PLC and gave the company a “buy” rating in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the stock. Endo International PLC currently has a consensus rating of “Hold” and an average target price of $14.75.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.